Medical innovations company BTG, continued its progress on the
strategy it implemented last May by revealing its operating
highlights that has seen six new programmes added to its product
pipeline.
Medical innovations firm BTG reported a full year pre-tax profit,
driven by growing recurring revenues and litigation settlements
that threatened to dissolve into a long running legal dispute.
Italy's Abiogen Pharma has licensed rights to two UK-developed
compounds that seem to work via a completely new mechanism of
action for the treatment of anxiety.